Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
Nurix Therapeutics reports 2021 executive compensation
By ExecPay News
Published: March 25, 2022
Nurix Therapeutics reported fiscal year 2021 executive compensation information on March 25, 2022.
In 2021, five executives at Nurix Therapeutics received on average a compensation package of $3.5M, a 47% decrease compared to previous year.
Average pay of disclosed executives at Nurix Therapeutics
Stefani A. Wolff, Chief Operating Officer, received $7.1M in total. 95% of Wolff's compensation, or $6.8M, was in option awards. Wolff also received $150K in bonus, $68K in non-equity incentive plan, $165K in salary, as well as $4.9K in other compensation.
Arthur T. Sands, Chief Executive Officer, received a compensation package of $4.8M, which decreased by 72% compared to previous year. 82% of the compensation package, or $3.9M, was in option awards.
Gwenn Hansen, Chief Scientific Officer, earned $2.3M in 2021, a 48% increase compared to previous year.
Hans van Houte, Chief Financial Officer, received $1.7M in 2021.
Christine Ring, General Counsel, earned $1.6M in 2021, a 26% increase compared to previous year.
Nurix Therapeutics' fiscal year ends on November 30.
Related executives
You may also like
Source: SEC filing on March 25, 2022.